Altasciences Welcomes Martin Poirier as Senior Director, Bioanalytical Sciences
12.11.2019 16:28:00 EET | Business Wire | Press release
Altasciences is pleased to announce the appointment of Martin Poirier, M.Sc., as Senior Director of Bioanalytical Sciences, based in Altasciences’ preclinical facility in Seattle, WA. Martin will apply his extensive knowledge and experience to guide internal and external clients throughout their bioanalysis and immunomodulation analysis projects.
Martin’s outstanding industry reputation and specialization in the field of immunology, as well as more than ten years of experience managing laboratory sciences and establishing new facilities across North America, align with Altasciences’ objective of continually enhancing their full service preclinical and clinical bioanalytical capabilities. He joins the Senior Management team, and takes on responsibilities for the growth and development of Altasciences’ preclinical bioanalytical business.
“We are very pleased to welcome Martin to our growing team of experts. His years of experience and breadth of knowledge will be an asset as we develop and enhance our facilities and offerings to fully and effectively support our clients’ ever-evolving needs,” said Mike Broadhurst, General Manager of Altasciences’ Seattle site.
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to preclinical and early phase clinical studies, from lead candidate selection to proof of concept. For over 25 years, Altasciences has been integrating into clients’ projects to help support educated, faster, and more complete early drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management, all of which can be tailored to specific sponsor requirements. Altasciences… helping sponsors get better drugs to the people who need them, faster.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191112005641/en/
Contact information
Julie-Ann Cabana
Altasciences
913 304-4505
jcabana@altasciences.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments21.4.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices. This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further expands the set of collaborations that Compass has established to inform the potential delivery of COMP360 in a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s network of over 1,000 clinics comprises one of the country’s largest network of interventional psychiatry practices. Its
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments21.4.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices. This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further expands the set of collaborations that Compass has established to inform the potential delivery of COMP360 in a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s network of over 1,000 clinics comprises one of the country’s largest network of interventional psychiatry practices. Its
Aventon Expands B2B Payment Terms Program to Germany with TreviPay21.4.2026 12:00:00 EEST | Press release
TreviPay, a global B2B payments infrastructure partner, today announced the expansion of its partnership with Aventon to support the launch of the Aventon Payment Terms program in Germany. Building on the success of Aventon’s existing program in the US and Canada, the new offering will give qualified B2B buyers in Germany access to invoicing and flexible payment terms designed to make purchasing easier and more predictable. As Aventon enters the German market and expands its presence in Europe, TreviPay will serve as the exclusive provider of payment terms for Aventon’s B2B buyers. The program is designed to help Aventon’s retail partners buy more confidently and manage working capital more effectively, while supporting the brand’s long-term growth in a new geography. By offering trade credit through TreviPay, Aventon can give retailers greater purchasing flexibility and strengthen its ability to compete in a dynamic market. TreviPay research shows 78% of B2B buyers say offering invoic
Aventon Expands B2B Payment Terms Program to Germany with TreviPay21.4.2026 12:00:00 EEST | Press release
TreviPay, a global B2B payments infrastructure partner, today announced the expansion of its partnership with Aventon to support the launch of the Aventon Payment Terms program in Germany. Building on the success of Aventon’s existing program in the US and Canada, the new offering will give qualified B2B buyers in Germany access to invoicing and flexible payment terms designed to make purchasing easier and more predictable. As Aventon enters the German market and expands its presence in Europe, TreviPay will serve as the exclusive provider of payment terms for Aventon’s B2B buyers. The program is designed to help Aventon’s retail partners buy more confidently and manage working capital more effectively, while supporting the brand’s long-term growth in a new geography. By offering trade credit through TreviPay, Aventon can give retailers greater purchasing flexibility and strengthen its ability to compete in a dynamic market. TreviPay research shows 78% of B2B buyers say offering invoic
Alpaca Expands into Europe with WealthKernel Acquisition and Launch of European Equities Trading21.4.2026 11:49:00 EEST | Press release
Alpaca, a global leader in brokerage infrastructure APIs, today announced the completion of its acquisition of European fintech WealthKernel, marking its expansion into Europe. The company also announced the initial rollout of its API-first equities trading services in Europe, enabling cross-border investing through a single integration. WealthKernel will now operate as Alpaca Europe. The acquisition gives Alpaca licensed brokerage and custody infrastructure in the UK and EU, supporting its ability to deliver investment services and expand its wealth management capabilities across the region. Built on WealthKernel’s regulatory and operational foundation, Alpaca Europe includes UK and EU licenses and local brokerage and custody infrastructure supporting products such as ISAs and SIPPs. Combined with Alpaca’s US-headquartered, licensed and regulated full-stack brokerage infrastructure, it creates a unified infrastructure layer for fintechs and financial institutions building investment p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom